体外診断市場 – 2030年までの世界予測

本レポートは、製品・サービス、技術、検​​体、検査場所、用途、エンドユーザー、地域に基づいて体外診断市場を分析しています。また、市場成長に影響を与える要因（推進要因、制約要因、機会、課題など）を分析するとともに、市場リーダーの競争環境の詳細を提供しています。さらに、ミクロ市場を個々の成長傾向に基づいて分析し、6つの主要地域（および各地域に属する国）における市場セグメントの収益予測も提供しています。

The global In vitro diagnostics market is projected to reach USD 157,632.5 million by 2030 from USD 109,065.5 million in 2025, at a CAGR of 7.6% during the forecast period. This is due to the increasing global burden of chronic diseases such as diabetes, cardiovascular conditions, cancer, and infectious diseases (e.g., HIV, tuberculosis). Demand for faster results, decentralized testing, and home-based diagnostics are pushing growth in point-of-care (POC) testing devices, innovations such as high-throughput systems, lab-on-a-chip, next-generation sequencing (NGS), and POC diagnostics, and government and private sector investments in healthcare infrastructure, especially in developing economies, are improving access to diagnostic services.

世界の体外診断市場は、2025年の1,090億6,550万米ドルから2030年には1,576億3,250万米ドルに達し、予測期間中は年平均成長率（CAGR）7.6%で成長すると予測されています。これは、糖尿病、心血管疾患、がん、感染症（HIV、結核など）といった慢性疾患の世界的な負担増加によるものです。迅速な結果、分散型検査、在宅診断への需要が、ポイントオブケア（POC）検査機器の成長を牽引しています。また、ハイスループットシステム、ラボオンチップ、次世代シーケンシング（NGS）、POC診断といったイノベーションの進展に加え、特に発展途上国における政府および民間セクターによる医療インフラへの投資が、診断サービスへのアクセス向上に寄与しています。

The reagents & kits segment is expected to grow at the highest CAGR during the forecast period.

Based on the product, the in vitro diagnostics market is divided into reagents & kits, instruments, and data management software & services. In 2024, the reagents & kits segment grew at the highest CAGR in vitro diagnostics market. This is due to the growing number of tests across hospitals, labs, and home settings, the expansion of rapid and self-testing kits, especially for glucose, pregnancy, and infectious disease detection, the expansion of clinical laboratories, diagnostic chains, and POC testing environments increases reagent usage. Continuous product launches and regulatory approvals—such as CE-IVD marking and FDA clearances—are expanding the portfolio and accessibility of specialized test kits across various clinical applications.

The infectious diseases segment of the in vitro diagnostics market, by application, is expected to hold the largest market share during the forecast period.

Based on application, the in vitro diagnostics market is segmented into infectious diseases, oncology, endocrinology, cardiology, blood screening, genetic testing, autoimmune diseases, allergy diagnostic, drug monitoring & testing, bone & mineral disorders, coagulation testing, blood group typing, and other applications. The infectious disease segment accounts for the largest market share of the in vitro diagnostics market due to the continued prevalence of diseases such as HIV, hepatitis, and tuberculosis, and emerging threats such as Malaria and Mpox, the need for fast, accessible testing—especially in remote or resource-limited settings—has boosted the adoption of portable and easy-to-use IVD kits for infectious diseases, and technologies such as RT-PCR (Reverse transcription polymerase chain reaction) and syndromic panel testing enable accurate, high-throughput diagnosis of multiple pathogens, driving growth in hospital and lab settings.

Asia Pacific is expected to hold the highest CAGR in the in vitro diagnostics market during the forecast period.

The global in vitro diagnostics market is segmented into six major regions, namely, North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC Countries. Asia Pacific is estimated to grow at the highest CAGR during the forecast period. The IVD market in the Asia Pacific region is growing rapidly due to the increasing prevalence of communicable and non-communicable diseases, especially in highly populated countries such as China and India. These countries are seeing a rise in conditions such as diabetes, cancer, cardiovascular diseases, tuberculosis, and hepatitis. Concurrently, the aging population is driving the IVD market in the Asia Pacific region, especially in Japan, South Korea, and China. For instance, within China, 216.76 million people are aged 65 and above, or 15.4% of the population, a 2023 report by China’s Ministry of Civil Affairs and the China National Committee on Aging stated. This trend is resulting in a growing demand for chronic disease monitoring and regular diagnostics. In an effort to increase local production and decrease the reliance on imports, regional governments are promoting the manufacture of diagnostic reagents, kits, and equipment locally, thus also fuelling the growth of the market.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1- 42%, Tier 2- 30%, and Tier 3- 28%
• By Designation: C-level- 46%, Director level- 23%, and Others- 31%
• By Region: North America- 23%, Europe- 45%, Asia Pacific- 28%, Latin America- 3%, Middle East & Africa- 0.5%, and GCC Countries- 0.5 %

Note 1: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.0 billion, Tier 2 = USD 1.0 billion to USD 10.0 billion, and Tier 3 = <USD 1.0 billion.

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the in vitro diagnostics market include Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Hologic, Inc. (US), Bio-Rad Laboratories, Inc. (US), bioMérieux  (France), Sysmex Corporation (Japan), Revvity (US), Becton, Dickinson and Company (US), Agilent Technologies, Inc. (US), Qiagen (Germany), DiaSorin S.p.A. (Italy), Grifols, S.A. (Spain), Werfen (Spain), and QuidelOrtho Corporation, (US) among others.

Research Coverage

This report studies the in vitro diagnostics market based on product & service, technology, specimen, site of testing, application, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to six major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to gain a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

This report provides insights on the following points:

• Analysis of key drivers (Increasing geriatric population and subsequent rise in chronic diseases, growing awareness of early disease diagnosis in emerging economies, emergence of rapid PoC technologies and rising adoption of automated analyzers, growing preference for personalized medicines), restraints (Unfavorable reimbursement scenario, stringent regulatory requirements, High cost of diagnostic equipment), opportunities (introduction of disease-specific biomarkers and tests, increasing significance of companion diagnostics, growth opportunities in developing countries, Improvements in immunoassay diagnostic technologies, digitalization trend), challenges (operational barriers, data privacy, and cybersecurity risks)

• Market Penetration: Complete knowledge of the spectrum of products presented by the major companies in the in vitro diagnostics market
• Product Development/Innovation: Comprehensive understanding of the forthcoming trends, research and development initiatives, and product launches within the in vitro diagnostics market
• Market Development: Complete knowledge about profitable developing regions
• Market Diversification: Exhaustive knowledge of new goods, expanding geographies, and current changes in the in vitro diagnostics industry helps to diversify the market
• Competitive Assessment: Comprehensive evaluation of market segmentation, development plans, income analysis, and goods of the top market participants

Table of Contents

1               INTRODUCTION              57

1.1           STUDY OBJECTIVES       57

1.2           MARKET DEFINITION   57

1.3           STUDY SCOPE   58

1.3.1        MARKETS COVERED AND REGIONAL SCOPE      58

1.3.2        INCLUSIONS AND EXCLUSIONS 59

1.3.3        YEARS CONSIDERED      60

1.4           CURRENCY CONSIDERED            60

1.5           STAKEHOLDERS               61

1.6           SUMMARY OF CHANGES               61

2               RESEARCH METHODOLOGY       62

2.1           RESEARCH DATA              62

2.1.1        SECONDARY RESEARCH                63

2.1.1.1    Key data from secondary sources       64

2.1.2        PRIMARY DATA 65

2.1.2.1    Primary sources    65

2.1.2.2    Key data from primary sources           66

2.1.2.3    Key industry insights           67

2.2           MARKET SIZE ESTIMATION         68

2.2.1        BOTTOM-UP APPROACH              69

2.2.1.1    Approach 1: Company revenue estimation approach     69

2.2.1.2    Approach 2: Presentations of companies and primary interviews                 70

2.2.1.3    Growth forecast    70

2.2.2        TOP-DOWN APPROACH                71

2.3           MARKET BREAKDOWN AND DATA TRIANGULATION                 72

2.4           MARKET SHARE ANALYSIS           73

2.5           RESEARCH ASSUMPTIONS           73

2.5.1        PARAMETRIC ASSUMPTIONS     73

2.5.2        GROWTH RATE ASSUMPTIONS 74

2.6           RESEARCH LIMITATIONS             74

2.7           RISK ASSESSMENT           74

3               EXECUTIVE SUMMARY  75

4               PREMIUM INSIGHTS       82

4.1           IN VITRO DIAGNOSTICS MARKET OVERVIEW    82

4.2           NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY, 2024          83

4.3           IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES         84

4.4           IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC MIX                 84

4.5           IN VITRO DIAGNOSTICS MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS                85

5               MARKET OVERVIEW       86

5.1           INTRODUCTION              86

5.2           MARKET DYNAMICS       86

5.2.1        DRIVERS               87

5.2.1.1    Increasing geriatric population and subsequent rise in chronic diseases  87

5.2.1.2    Growing awareness of early disease diagnosis in emerging economies              88

5.2.1.3    Emergence of rapid PoC technologies and rising adoption of automated analyzers             89

5.2.1.4    Growing preference for personalized medicines              89

5.2.2        RESTRAINTS      90

5.2.2.1    Unfavorable reimbursement scenario                90

5.2.2.2    Stringent regulatory requirements     90

5.2.2.3    High cost of diagnostic equipment    92

5.2.3        OPPORTUNITIES              92

5.2.3.1    Introduction of disease-specific biomarkers and tests    92

5.2.3.2    Increasing significance of companion diagnostics           93

5.2.3.3    Growth opportunities in developing countries                 94

5.2.3.4    Improvements in immunoassay diagnostic technologies                 95

5.2.3.5    Digitalization trend              96

5.2.4        CHALLENGES    96

5.2.4.1    Operational barriers             96

5.2.4.2    Data privacy and cybersecurity risks 97

5.3           TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS            98

5.4           PRICING ANALYSIS          98

5.4.1        AVERAGE SELLING PRICE TREND, BY KEY PLAYER                 98

5.4.2        AVERAGE SELLING PRICE TREND, BY REGION   100

5.4.3        AVERAGE SELLING PRICE TREND, BY PRODUCT                 100

5.5           VALUE CHAIN ANALYSIS               102

5.5.1        RESEARCH & DEVELOPMENT    102

5.5.2        RAW MATERIAL SUPPLIERS         102

5.5.3        MANUFACTURING          102

5.5.4        DISTRIBUTION, MARKETING, AND SALES             102

5.5.5        RETAILERS          102

5.5.6        POST-SALES SERVICES  102

5.6           SUPPLY CHAIN ANALYSIS             103

5.6.1        PROMINENT COMPANIES            103

5.6.2        SMALL & MEDIUM-SIZED ENTERPRISES 104

5.6.3        END USERS         104

5.7           ECOSYSTEM ANALYSIS  104

5.8           INVESTMENT AND FUNDING SCENARIO               106

5.9           TECHNOLOGY ANALYSIS             107

5.9.1        KEY TECHNOLOGIES     107

5.9.2        COMPLEMENTARY TECHNOLOGIES       108

5.9.2.1    Immunohistochemistry        108

5.10         PATENT ANALYSIS          109

5.11         TRADE ANALYSIS             111

5.11.1      IMPORT DATA FOR HS CODE 382200       111

5.11.2      EXPORT DATA FOR HS CODE 382200       112

5.12         KEY CONFERENCES AND EVENTS, 2025–2026        112

5.13         CASE STUDY ANALYSIS 113

5.13.1      CASE STUDY 1: LOCALIZED STRATEGY TO TAP MARKET POTENTIAL IN EUROPE                113

5.13.2      CASE STUDY 2: ENHANCED COMPANY FOOTPRINT IN

COMPETITIVE INDIAN MARKET                114

5.13.3      CASE STUDY 3: CUSTOMER-CENTRIC DIFFERENTIATION FOR PRODUCT OPTIMIZATION AND PREMIUM PRICING         115

5.14         REGULATORY LANDSCAPE         115

5.14.1      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             116

5.15         REGULATORY FRAMEWORK       118

5.15.1      NORTH AMERICA             118

5.15.1.1  US           118

5.15.1.2  Canada   120

5.15.2      EUROPE               120

5.15.3      ASIA PACIFIC     122

5.15.3.1  Japan      122

5.15.3.2  China      123

5.15.3.3  India       124

5.15.3.4  South Korea           124

5.15.3.5  Indonesia                125

5.15.3.6  Russia     126

5.15.4      MIDDLE EAST & AFRICA                126

5.15.4.1  Saudi Arabia          126

5.15.4.2  Africa      127

5.15.5      LATIN AMERICA                127

5.15.5.1  Mexico   127

5.15.5.2  Brazil      128

5.16         PORTER’S FIVE FORCES ANALYSIS           128

5.16.1      BARGAINING POWER OF SUPPLIERS       130

5.16.2      BARGAINING POWER OF BUYERS             130

5.16.3      THREAT OF NEW ENTRANTS      130

5.16.4      THREAT OF SUBSTITUTES          130

5.16.5      INTENSITY OF COMPETITIVE RIVALRY 130

5.17         KEY STAKEHOLDERS AND BUYING CRITERIA     131

5.17.1      KEY STAKEHOLDERS IN BUYING PROCESS           131

5.17.2      BUYING CRITERIA           132

5.18         RECENT POLICY CHANGES IN US MARKET AND THEIR POTENTIAL IMPACT ON APPROVAL PROCESS   133

5.19         INFLUENCE OF TARIFFS ON SUPPLY CHAIN RESILIENCE OF MEDTECH COMPANIES          135

5.20         GROWTH OF DECENTRALIZED TESTING VS. ADOPTION OF COST-EFFECTIVE CENTRALIZED TESTING   136

5.21         IMPACT OF AI/GENERATIVE AI ON IN VITRO DIAGNOSTICS MARKET 138

5.21.1      INTRODUCTION              138

5.21.2      MARKET POTENTIAL OF AI IN IVD DEVICES       138

5.21.3      AI USE CASES     139

5.21.4      KEY COMPANIES IMPLEMENTING AI      140

5.21.5      FUTURE OF GENERATIVE AI IN IN VITRO DIAGNOSTICS MARKET               140

6               IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE               141

6.1           INTRODUCTION              142

6.2           REAGENTS & KITS            142

6.2.1        RISE IN TEST VOLUMES ACROSS CLINICAL LABS, HOSPITALS, AND POINT-OF-CARE SETTINGS TO AID GROWTH                 142

6.3           INSTRUMENTS 146

6.3.1        GROWING TREND OF AUTOMATION TO DRIVE MARKET               146

6.4           DATA MANAGEMENT SOFTWARE & SERVICES   151

6.4.1        INCREASING SHIFT TOWARD CLOUD-BASED PLATFORMS AND REMOTE DATA ACCESS TO STIMULATE GROWTH             151

7               IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY                 156

7.1           INTRODUCTION              157

7.2           IMMUNOASSAYS              157

7.2.1        ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)                 162

7.2.1.1    Increasing use of immunoassays in cancer, infectious disease testing, and therapeutic drug monitoring to aid growth 162

7.2.2        CHEMILUMINESCENCE IMMUNOASSAYS              166

7.2.2.1    Need for minimal human intervention to support growth                 166

7.2.3        IMMUNOFLUORESCENCE ASSAYS            171

7.2.3.1    Growing introduction of innovative diagnostic platforms to drive market    171

7.2.4        RAPID TESTS     174

7.2.4.1    Need for rapid diagnostic tests to expedite growth         174

7.2.5        ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT)                 178

7.2.5.1    Need for early detection and monitoring of immune-related disorders to amplify growth                 178

7.2.6        WESTERN BLOTTING     182

7.2.6.1    Increasing focus on biomarker discovery and personalized treatment to advance growth              182

7.2.7        OTHER IMMUNOASSAY TECHNOLOGIES              185

7.3           CLINICAL CHEMISTRY   188

7.3.1        BASIC METABOLIC PANELS         194

7.3.1.1    Increasing incidence of diabetes, kidney disorders, and hypertension to promote growth        194

7.3.2        LIVER PANELS   197

7.3.2.1    Rising prevalence of cirrhosis and viral hepatitis to foster growth                 197

7.3.3        RENAL PROFILES             201

7.3.3.1    Growing awareness for preventive health check-ups to boost market    201

7.3.4        LIPID PROFILES                204

7.3.4.1    Rising prevalence of obesity to accelerate growth           204

7.3.5        THYROID FUNCTION PROFILES                208

7.3.5.1    High incidence of thyroid-related disorders to support growth                 208

7.3.6        ELECTROLYTE PANELS 211

7.3.6.1    Growing shift toward home care and remote patient monitoring to fuel market        211

7.3.7        SPECIALTY CHEMICAL TESTS    215

7.3.7.1    Rising demand for specialized tests to contribute to growth                 215

7.4           MOLECULAR DIAGNOSTICS       218

7.4.1        POLYMERASE CHAIN REACTION               223

7.4.1.1    High accuracy and speed in detecting pathogens to aid growth                 223

7.4.2        ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY  227

7.4.2.1    Growing focus on rapid, onsite molecular diagnostics to propel market    227

7.4.3        DNA SEQUENCING & NEXT-GENERATION SEQUENCING                 231

7.4.3.1    Growing applications in research, drug discovery, and molecular diagnostics to boost market 231

7.4.4        IN SITU HYBRIDIZATION              235

7.4.4.1    Rising prevalence of cancer and genetic disorders to assist growth                 235

7.4.5        DNA MICROARRAYS        238

7.4.5.1    High resolution and throughput capabilities to favor growth                 238

7.4.6        OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES                 241

7.5           GLUCOSE MONITORING               244

7.5.1        ONGOING TECHNOLOGICAL ADVANCEMENTS IN BLOOD GLUCOSE SELF-MONITORING DEVICES TO AID GROWTH             244

7.6           HEMATOLOGY 248

7.6.1        GROWING FOCUS ON STEM CELL RESEARCH TO BOOST MARKET               248

7.7           MICROBIOLOGY               251

7.7.1        RISING PREVALENCE OF MICROBIAL INFECTIONS TO SUSTAIN GROWTH          251

7.8           COAGULATION & HEMOSTASIS 254

7.8.1        GROWING CASES OF PULMONARY EMBOLISM, HEMOPHILIA, LIVER DISEASES TO DRIVE MARKET          254

7.9           BLOOD GAS ANALYZERS              258

7.9.1        GROWING SURGICAL INTERVENTIONS AND RISE IN ELDERLY POPULATION TO FUEL MARKET          258

7.10         URINALYSIS        262

7.10.1      RISING INCIDENCE OF URINARY TRACT INFECTIONS TO SUPPORT GROWTH 262

7.11         CHROMATOGRAPHY & MASS SPECTROMETRY  265

7.11.1      INCREASING APPLICATIONS IN DISEASE SCREENING AND DIAGNOSTICS TO AID GROWTH    265

8               IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN                 270

8.1           INTRODUCTION              271

8.2           BLOOD, SERUM, AND PLASMA SPECIMENS          271

8.2.1        GROWING SHIFT TOWARD DECENTRALIZED TESTING TO PROPEL MARKET      271

8.3           SALIVA SPECIMENS         275

8.3.1        GROWING ADVANCEMENTS IN MOLECULAR DIAGNOSTICS

TO BOOST MARKET     275

8.4           URINE SPECIMENS          278

8.4.1        RISING INCIDENCE OF URINARY TRACT INFECTIONS TO ACCELERATE GROWTH         278

8.5           OTHER SPECIMENS        282

9               IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING                 286

9.1           INTRODUCTION              287

9.2           LABORATORY TESTS     287

9.2.1        INCREASING FOCUS ON EARLY AND ACCURATE DISEASE DETECTION TO ENCOURAGE GROWTH              287

9.3           POINT-OF-CARE TESTS 293

9.3.1        RISING DEMAND FOR DECENTRALIZED HEALTHCARE TO CONTRIBUTE TO GROWTH 293

10            IN VITRO DIAGNOSTICS MARKET, BY APPLICATION                 299

10.1         INTRODUCTION              300

10.2         INFECTIOUS DISEASES 301

10.2.1      INCREASING PREVALENCE OF VIRAL, BACTERIAL, AND PARASITIC INFECTIONS TO PROMOTE GROWTH              301

10.3         ONCOLOGY        304

10.3.1      RISING GLOBAL BURDEN OF CANCER TO EXPEDITE GROWTH             304

10.4         ENDOCRINOLOGY          308

10.4.1      INCREASING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO BOLSTER GROWTH                 308

10.5         CARDIOLOGY    312

10.5.1      GROWING USE OF IMMUNOASSAYS IN CARDIOVASCULAR DISEASE DETECTION TO DRIVE MARKET                 312

10.6         BLOOD SCREENING        315

10.6.1      RISING INCIDENCE OF HIV AND SYPHILIS TO SUPPORT GROWTH             315

10.7         GENETIC TESTING          319

10.7.1      INCREASING CLINICAL UTILITY OF GENETIC TESTS ACROSS ONCOLOGY, RARE DISEASES, AND REPRODUCTIVE HEALTH TO FOSTER GROWTH 319

10.8         AUTOIMMUNE DISEASES             322

10.8.1      RISE IN AUTOIMMUNE CONDITIONS GLOBALLY TO FACILITATE GROWTH   322

10.9         ALLERGY DIAGNOSTICS               326

10.9.1      INCREASING AWARENESS ABOUT ALLERGIES TO AMPLIFY GROWTH          326

10.10       DRUG MONITORING & TESTING               330

10.10.1   INCREASING ILLICIT DRUG CONSUMPTION TO SUSTAIN GROWTH          330

10.11       BONE & MINERAL DISORDERS   334

10.11.1   RISING CASES OF OSTEOPOROSIS TO FUEL MARKET                 334

10.12       COAGULATION TESTING             338

10.12.1   INCREASING PREVALENCE OF HEMOPHILIA TO ADVANCE GROWTH       338

10.13       BLOOD GROUP TYPING                341

10.13.1   RISING NUMBER OF SURGICAL PROCEDURES TO SPEED UP GROWTH      341

10.14       OTHER APPLICATIONS 345

11            IN VITRO DIAGNOSTICS MARKET, BY END USER                 349

11.1         INTRODUCTION              350

11.2         HOSPITALS & CLINICS   350

11.2.1      EXPANDING HEALTHCARE INFRASTRUCTURE TO SPEED UP GROWTH        350

11.3         CLINICAL LABORATORIES           354

11.3.1      LARGE REFERENCE LABORATORIES       358

11.3.1.1  Growing test volume and complexity of diagnostic testing to propel market        358

11.3.2      SMALL AND MEDIUM-SIZED LABORATORIES     361

11.3.2.1  Increasing shift toward community-based and point-of-care settings to foster growth      361

11.4         BLOOD BANKS  364

11.4.1      NEED TO ADDRESS PUBLIC HEALTH AND SAFETY CHALLENGES TO AID GROWTH                364

11.5         HOME CARE SETTINGS 368

11.5.1      GROWING INCLINATION TOWARD SELF-DIAGNOSIS AND MONITORING TO BOOST MARKET                368

11.6         PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES                 372

11.6.1      INCREASING USE OF IVD PRODUCTS IN CLINICAL DRUG DEVELOPMENT AND COMPANION DIAGNOSTICS TO DRIVE MARKET               372

11.7         ACADEMIC INSTITUTES                375

11.7.1      RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO AUGMENT GROWTH       375

11.8         OTHER END USERS         378

12            IN VITRO DIAGNOSTICS MARKET, BY REGION   382

12.1         INTRODUCTION              383

12.2         NORTH AMERICA             383

12.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 384

12.2.2      US           392

12.2.2.1  Established reimbursement framework and favorable policies for IVD providers to drive market            392

12.2.3      CANADA               399

12.2.3.1  Favorable funding initiatives for early disease diagnosis to fuel market    399

12.3         EUROPE               405

12.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      406

12.3.2      GERMANY           413

12.3.2.1  Increasing investments in clinical diagnostics research to aid growth    413

12.3.3      FRANCE                418

12.3.3.1  High healthcare expenditure and rising investments in genomic medicine to drive market    418

12.3.4      UK          424

12.3.4.1  Rising adoption of genome-based testing to encourage growth                 424

12.3.5      ITALY    430

12.3.5.1  Growing geriatric population and subsequent rise in chronic conditions to boost market 430

12.3.6      SPAIN    436

12.3.6.1  Increasing adoption of technologically advanced immunoassay systems to expedite growth 436

12.3.7      RUSSIA 441

12.3.7.1  High incidence of respiratory infectious diseases to boost market                 441

12.3.8      SWITZERLAND 447

12.3.8.1  Growing prevalence of chronic diseases to propel market                 447

12.3.9      REST OF EUROPE             453

12.4         ASIA PACIFIC     459

12.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 460

12.4.2      JAPAN   468

12.4.2.1  Increasing research investments for immunoassays to encourage growth    468

12.4.3      CHINA  473

12.4.3.1  Growing focus on preventive care to boost market         473

12.4.4      INDIA    479

12.4.4.1  Rising incidence of diabetes and cancer to augment growth                 479

12.4.5      SOUTH KOREA  485

12.4.5.1  Rising healthcare spending for innovative IVD technologies to amplify growth      485

12.4.6      AUSTRALIA         491

12.4.6.1  Increasing incidence of chronic diseases and rising blood donations to fuel market      491

12.4.7      SINGAPORE        497

12.4.7.1  Rising technological advancements and automation to stimulate growth    497

12.4.8      REST OF ASIA PACIFIC   502

12.5         LATIN AMERICA                508

12.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 508

12.5.2      BRAZIL 514

12.5.2.1  Rising prevalence of diabetes to sustain growth               514

12.5.3      MEXICO                520

12.5.3.1  Growing establishment of clinical laboratories to fuel market                 520

12.5.4      REST OF LATIN AMERICA             526

12.6         MIDDLE EAST & AFRICA                533

12.6.1      GROWING FOCUS ON PRENATAL AND CANCER TESTING TO DRIVE MARKET      533

12.6.2      MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK                 533

12.7         GCC COUNTRIES              538

12.7.1      GCC COUNTRIES: MACROECONOMIC OUTLOOK                 539

12.7.2      SAUDI ARABIA  544

12.7.2.1  Rising government healthcare expenditure to boost market                 544

12.7.3      UAE        550

12.7.3.1  Improvements in healthcare infrastructure to support growth                 550

12.7.4      OTHER GCC COUNTRIES              555

13            COMPETITIVE LANDSCAPE         561

13.1         OVERVIEW          561

13.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            561

13.3         OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS                 562

13.4         REVENUE ANALYSIS, 2022–2024  563

13.5         MARKET SHARE ANALYSIS, 2024                 564

13.6         COMPANY VALUATION AND FINANCIAL METRICS                 566

13.7         BRAND/PRODUCT COMPARISON             567

13.8         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 568

13.8.1      STARS   568

13.8.2      EMERGING LEADERS     568

13.8.3      PERVASIVE PLAYERS      568

13.8.4      PARTICIPANTS 568

13.8.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         570

13.8.5.1  Company footprint               570

13.8.5.2  Region footprint   571

13.8.5.3  Product & service footprint 572

13.8.5.4  Technology footprint           573

13.8.5.5  End-user footprint                574

13.9         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        575

13.9.1      PROGRESSIVE COMPANIES         575

13.9.2      RESPONSIVE COMPANIES            575

13.9.3      DYNAMIC COMPANIES  575

13.9.4      STARTING BLOCKS         575

13.9.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 577

13.9.5.1  Detailed list of key startups/SMEs    577

13.9.5.2  Competitive benchmarking of key startups/SMEs          578

13.10       COMPETITIVE SCENARIO             579

13.10.1   PRODUCT LAUNCHES AND APPROVALS               579

13.10.2   DEALS  580

13.10.3   EXPANSIONS     581

13.11       POTENTIAL FUTURISTIC STRATEGIES OF LEADING PLAYERS OPERATING IN IVD MARKET   582

13.11.1   PRODUCT LAUNCHES AND APPROVALS               583

13.11.2   DEALS  583

14            COMPANY PROFILES      585

14.1         KEY PLAYERS     585

14.1.1      DANAHER            585

14.1.1.1  Business overview 585

14.1.1.2  Products/Services offered   587

14.1.1.3  Recent developments           590

14.1.1.3.1                Product launches and approvals         590

14.1.1.3.2                Deals      591

14.1.1.3.3                Expansions             592

14.1.1.4  MnM view              593

14.1.1.4.1                Key strengths        593

14.1.1.4.2                Strategic choices   593

14.1.1.4.3                Weaknesses and competitive threats 593

14.1.2      F. HOFFMANN-LA ROCHE LTD  594

14.1.2.1  Business overview 594

14.1.2.2  Products/Services offered   596

14.1.2.3  Recent developments           599

14.1.2.3.1                Product launches and approvals         599

14.1.2.3.2                Deals      601

14.1.2.3.3                Expansions             602

14.1.2.4  MnM view              602

14.1.2.4.1                Key strengths        602

14.1.2.4.2                Strategic choices   602

14.1.2.4.3                Weaknesses and competitive threats 602

14.1.3      ABBOTT               603

14.1.3.1  Business overview 603

14.1.3.2  Products/Services offered   604

14.1.3.3  Recent developments           607

14.1.3.3.1                Product launches and approvals         607

14.1.3.3.2                Deals      608

14.1.3.3.3                Expansions             609

14.1.3.4  MnM view              609

14.1.3.4.1                Key strengths        609

14.1.3.4.2                Strategic choices   609

14.1.3.4.3                Weakness and competitive threats     609

14.1.4      SIEMENS HEALTHINEERS AG      610

14.1.4.1  Business overview 610

14.1.4.2  Products/Services offered   612

14.1.4.3  Recent developments           614

14.1.4.3.1                Product launches and approvals         614

14.1.4.3.2                Deals      614

14.1.4.3.3                Expansions             616

14.1.4.4  MnM view              616

14.1.4.4.1                Key strengths        616

14.1.4.4.2                Strategic choices   616

14.1.4.4.3                Weaknesses and competitive threats 616

14.1.5      THERMO FISHER SCIENTIFIC INC.            617

14.1.5.1  Business overview 617

14.1.5.2  Products/Services offered   618

14.1.5.3  Recent developments           621

14.1.5.3.1                Product launches and approvals         621

14.1.5.3.2                Deals      622

14.1.5.3.3                Expansions             624

14.1.5.4  MnM view              624

14.1.5.4.1                Key strengths        624

14.1.5.4.2                Strategic choices   624

14.1.5.4.3                Weaknesses and competitive threats 625

14.1.6      ILLUMINA, INC. 626

14.1.6.1  Business overview 626

14.1.6.2  Products/Services offered   628

14.1.6.3  Recent developments           629

14.1.6.3.1                Product launches and approvals         629

14.1.6.3.2                Deals      630

14.1.6.3.3                Expansions             631

14.1.6.3.4                Other developments             632

14.1.7      HOLOGIC, INC. 633

14.1.7.1  Business overview 633

14.1.7.2  Products/Services offered   634

14.1.7.3  Recent developments           635

14.1.7.3.1                Product launches and approvals         635

14.1.7.3.2                Deals      636

14.1.7.3.3                Expansions             637

14.1.8      BIO-RAD LABORATORIES, INC.  638

14.1.8.1  Business overview 638

14.1.8.2  Products/Services offered   640

14.1.8.3  Recent developments           642

14.1.8.3.1                Product launches and approvals         642

14.1.8.3.2                Deals      643

14.1.9      BIOMÉRIEUX     644

14.1.9.1  Business overview 644

14.1.9.2  Products/Services offered   646

14.1.9.3  Recent developments           648

14.1.9.3.1                Product launches and approvals         648

14.1.9.3.2                Deals      649

14.1.9.3.3                Expansions             650

14.1.10   SYSMEX CORPORATION                651

14.1.10.1                 Business overview 651

14.1.10.2                 Products/Services offered   653

14.1.10.3                 Recent developments           654

14.1.10.3.1             Product launches and approvals         654

14.1.10.3.2             Deals      655

14.1.10.3.3             Expansions             656

14.1.11   REVVITY               657

14.1.11.1                 Business overview 657

14.1.11.2                 Products/Services offered   659

14.1.11.3                 Recent developments           660

14.1.11.3.1             Product launches and approvals         660

14.1.11.3.2             Deals      661

14.1.11.3.3             Other developments             661

14.1.12   BECTON, DICKINSON AND COMPANY   662

14.1.12.1                 Business overview 662

14.1.12.2                 Products/Services offered   663

14.1.12.3                 Recent developments           666

14.1.12.3.1             Product launches and approvals         666

14.1.12.3.2             Deals      666

14.1.12.3.3             Expansions             667

14.1.13   AGILENT TECHNOLOGIES, INC.                668

14.1.13.1                 Business overview 668

14.1.13.2                 Products/Services offered   670

14.1.13.3                 Recent developments           672

14.1.13.3.1             Product launches and approvals         672

14.1.13.3.2             Deals      673

14.1.13.3.3             Other developments             674

14.1.14   QIAGEN                675

14.1.14.1                 Business overview 675

14.1.14.2                 Products/Services offered   677

14.1.14.3                 Recent developments           680

14.1.14.3.1             Product launches and approvals         680

14.1.14.3.2             Deals      682

14.1.15   DIASORIN S.P.A.                683

14.1.15.1                 Business overview 683

14.1.15.2                 Products/Services offered   685

14.1.15.3                 Recent developments           687

14.1.15.3.1             Product launches and approvals         687

14.1.15.3.2             Deals      688

14.1.16   GRIFOLS, S.A.     689

14.1.16.1                 Business overview 689

14.1.16.2                 Products/Services offered   691

14.1.16.3                 Recent developments           691

14.1.16.3.1             Product launches and approvals         691

14.1.16.3.2             Deals      692

14.1.17   WERFEN               693

14.1.17.1                 Business overview 693

14.1.17.2                 Products/Services offered   695

14.1.17.2.1             Deals      696

14.1.17.2.2             Expansions             697

14.1.18   QUIDELORTHO CORPORATION                698

14.1.18.1                 Business overview 698

14.1.18.2                 Products/Services offered   700

14.1.18.3                 Recent developments           702

14.1.18.3.1             Product launches and approvals         702

14.1.18.3.2             Deals      703

14.1.18.3.3             Expansions             703

14.2         OTHER PLAYERS              704

14.2.1      DEVYSER             704

14.2.2      BIOSYNEX SA     705

14.2.3      SURMODICS, INC.            706

14.2.4      MENARINI SILICON BIOSYSTEMS             707

14.2.5      SPEEDX PTY. LTD.           708

14.2.6      GENSPEED BIOTECH GMBH       709

14.2.7      MERCK KGAA    710

14.2.8      CARIS LIFE SCIENCES     712

14.2.9      ARKRAY, INC.     713

14.2.10   ACCELERATE DIAGNOSTICS, INC.            714

14.2.11   CELLABS              715

14.2.12   J. MITRA & CO. PVT. LTD.             716

14.2.13   EPITOPE DIAGNOSTICS, INC.     717

14.2.14   BOSTER BIOLOGICAL TECHNOLOGY     718

14.2.15   ENZO BIOCHEM INC.     719

14.2.16   GENETIC SIGNATURES 720

14.2.17   SAVYON DIAGNOSTICS 721

14.2.18   TRIVITRON HEALTHCARE           722

14.2.19   MDXHEALTH     723

14.2.20   CREATIVE DIAGNOSTICS             724

14.2.21   INBIOS INTERNATIONAL, INC.  725

14.2.22   MACCURA BIOTECHNOLOGY CO., LTD.                726

14.2.23   LUYE LIFE SCIENCES GROUP      727

15            APPENDIX           728

15.1         DISCUSSION GUIDE        728

15.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                735

15.3         CUSTOMIZATION OPTIONS        737

15.4         RELATED REPORTS         738

15.5         AUTHOR DETAILS           739

LIST OF TABLES

TABLE 1                IN VITRO DIAGNOSTICS MARKET: INCLUSIONS AND EXCLUSIONS           59

TABLE 2                IN VITRO DIAGNOSTICS MARKET: RISK ASSESSMENT     74

TABLE 3                ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION, 2022−2050    87

TABLE 4                IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES, 2022−2024  89

TABLE 5                APPLICATION OF CANCER BIOMARKERS IN CLINICAL PRACTICE      92

TABLE 6                RECENT DEVELOPMENTS IN IVD MARKET, 2021–2023              95

TABLE 7                AVERAGE SELLING PRICE TREND OF IVD PRODUCTS, BY KEY PLAYER,

2022–2024 (USD)                99

TABLE 8                AVERAGE SELLING PRICE TREND OF CLINICAL CHEMISTRY ANALYZERS,

BY REGION, 2022–2024 (USD)      100

TABLE 9                AVERAGE SELLING PRICE TREND OF IVD PRODUCTS, BY TYPE, 2022–2024 (USD)  101

TABLE 10              IN VITRO DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM       105

TABLE 11              IN VITRO DIAGNOSTICS MARKET: INNOVATIONS AND PATENT

REGISTRATIONS, 2022−2024        110

TABLE 12              IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2024 (USD MILLION)     111

TABLE 13              EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2024 (USD MILLION)     112

TABLE 14              IN VITRO DIAGNOSTICS MARKET: KEY CONFERENCES AND EVENTS, 2025−2026               112

TABLE 15              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 116

TABLE 16              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  116

TABLE 17              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  117

TABLE 18              LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  117

TABLE 19              REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  118

TABLE 20              US: CLASSIFICATION OF IVD DEVICES   118

TABLE 21              EUROPE: CLASSIFICATION OF IVD DEVICES                 121

TABLE 22              JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN   123

TABLE 23              JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS             123

TABLE 24              CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS             123

TABLE 25              SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS      124

TABLE 26              INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES              125

TABLE 27              RUSSIA: CLASSIFICATION OF IVD DEVICES                 126

TABLE 28              SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS      126

TABLE 29              MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS             128

TABLE 30              IN VITRO DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 129

TABLE 31              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD PRODUCTS (%)              131

TABLE 32              KEY BUYING CRITERIA, BY PRODUCT & SERVICE                 132

TABLE 33              US: OVERVIEW OF CERTAIN KEY CATEGORIES OF IVD DEVICES               134

TABLE 34              TARIFF RATES IMPOSED BY US, AS OF APRIL 2025        135

TABLE 35              COMPARATIVE ANALYSIS OF CENTRALIZED VS. DECENTRALIZED TESTING         137

TABLE 36              IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            142

TABLE 37              IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION,

2022–2030 (USD MILLION)            144

TABLE 38              NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS,

BY COUNTRY, 2022–2030 (USD MILLION)               144

TABLE 39              EUROPE: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2030 (USD MILLION)                 145

TABLE 40              ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS,

BY COUNTRY, 2022–2030 (USD MILLION)               145

TABLE 41              LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS,

BY COUNTRY, 2022–2030 (USD MILLION)               146

TABLE 42              GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS,

BY COUNTRY, 2022–2030 (USD MILLION)               146

TABLE 43              KEY IVD INSTRUMENTS AVAILABLE WORLDWIDE     147

TABLE 44              IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION,

2022–2030 (USD MILLION)            148

TABLE 45              NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS,

BY COUNTRY, 2022–2030 (USD MILLION)               149

TABLE 46              EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION)                 149

TABLE 47              ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2030 (USD MILLION)                 150

TABLE 48              LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS,

BY COUNTRY, 2022–2030 (USD MILLION)               150

TABLE 49              GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS,

BY COUNTRY, 2022–2030 (USD MILLION)               150

TABLE 50              KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE WORLDWIDE   152

TABLE 51              IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY REGION, 2022–2030 (USD MILLION) 153

TABLE 52              NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)     153

TABLE 53              EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)            154

TABLE 54              ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)     154

TABLE 55              LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)     155

TABLE 56              GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE & SERVICES, BY COUNTRY, 2022–2030 (USD MILLION)     155

TABLE 57              IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            157

TABLE 58              KEY IMMUNOASSAY ANALYZERS AVAILABLE WORLDWIDE     158

TABLE 59              IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,

2022–2030 (USD MILLION)            159

TABLE 60              IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION,

2022–2030 (USD MILLION)            160

TABLE 61              NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS,

BY COUNTRY, 2022–2030 (USD MILLION)               160

TABLE 62              EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)                 161

TABLE 63              ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)                 161

TABLE 64              LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS,

BY COUNTRY, 2022–2030 (USD MILLION)               162

TABLE 65              GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS,

BY COUNTRY, 2022–2030 (USD MILLION)               162

TABLE 66              KEY ELISA ANALYZERS AVAILABLE WORLDWIDE     163

TABLE 67              IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY REGION, 2022–2030 (USD MILLION)            164

TABLE 68              NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)     164

TABLE 69              EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)            165

TABLE 70              ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)            165

TABLE 71              LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)     166

TABLE 72              GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)     166

TABLE 73              KEY CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE WORLDWIDE         168

TABLE 74              IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS,

BY REGION, 2022–2030 (USD MILLION)   168

TABLE 75              NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)     169

TABLE 76              EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)       169

TABLE 77              ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)            170

TABLE 78              LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)     170

TABLE 79              GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)     171

TABLE 80              IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS,

BY REGION, 2022–2030 (USD MILLION)   172

TABLE 81              NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)            172

TABLE 82              EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 173

TABLE 83              ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION) 173

TABLE 84              LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)            174

TABLE 85              GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)            174

TABLE 86              KEY RAPID TESTS AVAILABLE WORLDWIDE                 175

TABLE 87              IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY REGION,

2022–2030 (USD MILLION)            176

TABLE 88              NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS,

BY COUNTRY, 2022–2030 (USD MILLION)             176

TABLE 89              EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY,

2022–2030 (USD MILLION)            177

TABLE 90              ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022–2030 (USD MILLION)                 177

TABLE 91              LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2022–2030 (USD MILLION)            178

TABLE 92              GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS,

BY COUNTRY, 2022–2030 (USD MILLION)               178

TABLE 93              IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS,

BY REGION, 2022–2030 (USD MILLION)   179

TABLE 94              NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)     180

TABLE 95              EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)       180

TABLE 96              ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)            181

TABLE 97              LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)     181

TABLE 98              GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT ASSAYS, BY COUNTRY, 2022–2030 (USD MILLION)     182

TABLE 99              KEY WESTERN BLOTTING SYSTEMS AVAILABLE WORLDWIDE     183

TABLE 100            IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY REGION,

2022–2030 (USD MILLION)            183

TABLE 101            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING,

BY COUNTRY, 2022–2030 (USD MILLION)               183

TABLE 102            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2022–2030 (USD MILLION)                 184

TABLE 103            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING,

BY COUNTRY, 2022–2030 (USD MILLION)               184

TABLE 104            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING,

BY COUNTRY, 2022–2030 (USD MILLION)               185

TABLE 105            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING,

BY COUNTRY, 2022–2030 (USD MILLION)               185

TABLE 106            IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES,

BY REGION, 2022–2030 (USD MILLION)   186

TABLE 107            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)     186

TABLE 108            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)       187

TABLE 109            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)            187

TABLE 110            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)     188

TABLE 111            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)     188

TABLE 112            CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES AVAILABLE WORLDWIDE                 189

TABLE 113            CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES AVAILABLE WORLDWIDE        190

TABLE 114            IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE,

2022–2030 (USD MILLION)            191

TABLE 115            IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY REGION,

2022–2030 (USD MILLION)            191

TABLE 116            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,

BY COUNTRY, 2022–2030 (USD MILLION)               192

TABLE 117            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,

BY COUNTRY, 2022–2030 (USD MILLION)               192

TABLE 118            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,

BY COUNTRY, 2022–2030 (USD MILLION)             193

TABLE 119            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,

BY COUNTRY, 2022–2030 (USD MILLION)               193

TABLE 120            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,

BY COUNTRY, 2022–2030 (USD MILLION)               194

TABLE 121            IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY REGION, 2022–2030 (USD MILLION)                 195

TABLE 122            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION)       195

TABLE 123            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS,

BY COUNTRY, 2022–2030 (USD MILLION)               196

TABLE 124            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS,

BY COUNTRY, 2022–2030 (USD MILLION)               196

TABLE 125            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION)       197

TABLE 126            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2022–2030 (USD MILLION)       197

TABLE 127            IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY REGION,

2022–2030 (USD MILLION)            198

TABLE 128            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS,

BY COUNTRY, 2022–2030 (USD MILLION)               199

TABLE 129            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022–2030 (USD MILLION)                 199

TABLE 130            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2022–2030 (USD MILLION)                 200

TABLE 131            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS,

BY COUNTRY, 2022–2030 (USD MILLION)               200

TABLE 132            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS,

BY COUNTRY, 2022–2030 (USD MILLION)               201

TABLE 133            IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY REGION,

2022–2030 (USD MILLION)            202

TABLE 134            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES,

BY COUNTRY, 2022–2030 (USD MILLION)               202

TABLE 135            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)                 203

TABLE 136            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES,

BY COUNTRY, 2022–2030 (USD MILLION)               203

TABLE 137            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES,

BY COUNTRY, 2022–2030 (USD MILLION)               204

TABLE 138            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES,

BY COUNTRY, 2022–2030 (USD MILLION)               204

TABLE 139            IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY REGION,

2022–2030 (USD MILLION)            205

TABLE 140            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES,

BY COUNTRY, 2022–2030 (USD MILLION)               206

TABLE 141            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)                 206

TABLE 142            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)                 207

TABLE 143            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES,

BY COUNTRY, 2022–2030 (USD MILLION)             207

TABLE 144            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES,

BY COUNTRY, 2022–2030 (USD MILLION)               208

TABLE 145            IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY REGION, 2022–2030 (USD MILLION)                 209

TABLE 146            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)            209

TABLE 147            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES,

BY COUNTRY, 2022–2030 (USD MILLION)               210

TABLE 148            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION) 210

TABLE 149            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)            211

TABLE 150            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2022–2030 (USD MILLION)            211

TABLE 151            REFERENCE RANGES AND ABNORMAL CONDITIONS FOR KEY ELECTROLYTES 212

TABLE 152            IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY REGION,

2022–2030 (USD MILLION)            213

TABLE 153            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS,

BY COUNTRY, 2022–2030 (USD MILLION)             213

TABLE 154            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS,

BY COUNTRY, 2022–2030 (USD MILLION)               214

TABLE 155            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS,

BY COUNTRY, 2022–2030 (USD MILLION)               214

TABLE 156            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS,

BY COUNTRY, 2022–2030 (USD MILLION)               215

TABLE 157            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS,

BY COUNTRY, 2022–2030 (USD MILLION)               215

TABLE 158            IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY REGION, 2022–2030 (USD MILLION)            216

TABLE 159            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION)       216

TABLE 160            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS,

BY COUNTRY, 2022–2030 (USD MILLION)               217

TABLE 161            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION) 217

TABLE 162            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION)       218

TABLE 163            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION)       218

TABLE 164            KEY AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE WORLDWIDE  219

TABLE 165            IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)                 220

TABLE 166            IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2022–2030 (USD MILLION)            220

TABLE 167            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)       221

TABLE 168            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,

BY COUNTRY, 2022–2030 (USD MILLION)               221

TABLE 169            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,

BY COUNTRY, 2022–2030 (USD MILLION)               222

TABLE 170            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)       222

TABLE 171            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2030 (USD MILLION)       223

TABLE 172            KEY POLYMERASE CHAIN REACTION INSTRUMENTS AVAILABLE WORLDWIDE             224

TABLE 173            IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022–2030 (USD MILLION)            225

TABLE 174            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION)            225

TABLE 175            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION,

BY COUNTRY, 2022–2030 (USD MILLION)               226

TABLE 176            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION) 226

TABLE 177            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION)            227

TABLE 178            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2030 (USD MILLION)            227

TABLE 179            KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY INSTRUMENTS AVAILABLE WORLDWIDE     229

TABLE 180            IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2022–2030 (USD MILLION)   229

TABLE 181            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)                 229

TABLE 182            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)               230

TABLE 183            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)                 230

TABLE 184            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)                 231

TABLE 185            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)                 231

TABLE 186            KEY NEXT-GENERATION SEQUENCING-BASED INSTRUMENTS

AVAILABLE WORLDWIDE             232

TABLE 187            IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2022–2030 (USD MILLION)            233

TABLE 188            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION) 233

TABLE 189            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION)     234

TABLE 190            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION)     234

TABLE 191            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION) 235

TABLE 192            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2030 (USD MILLION) 235

TABLE 193            IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION,

2022–2030 (USD MILLION)            236

TABLE 194            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,

BY COUNTRY, 2022–2030 (USD MILLION)               236

TABLE 195            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,

BY COUNTRY, 2022–2030 (USD MILLION)               237

TABLE 196            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,

BY COUNTRY, 2022–2030 (USD MILLION)               237

TABLE 197            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,

BY COUNTRY, 2022–2030 (USD MILLION)               238

TABLE 198            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,

BY COUNTRY, 2022–2030 (USD MILLION)               238

TABLE 199            IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION,

2022–2030 (USD MILLION)            239

TABLE 200            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS,

BY COUNTRY, 2022–2030 (USD MILLION)               239

TABLE 201            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2030 (USD MILLION)                 240

TABLE 202            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS,

BY COUNTRY, 2022–2030 (USD MILLION)               240

TABLE 203            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS,

BY COUNTRY, 2022–2030 (USD MILLION)               241

TABLE 204            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS,

BY COUNTRY, 2022–2030 (USD MILLION)               241

TABLE 205            IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY REGION, 2022–2030 (USD MILLION)       242

TABLE 206            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)                 242

TABLE 207            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)     243

TABLE 208            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)     243

TABLE 209            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)                 244

TABLE 210            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2022–2030 (USD MILLION)                 244

TABLE 211            DIABETES-RELATED HEALTH EXPENDITURE PER PERSON,

2021 VS. 2030 VS. 2045 (USD)        245

TABLE 212            IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY REGION,

2022–2030 (USD MILLION)          246

TABLE 213            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING, BY COUNTRY, 2022–2030 (USD MILLION) 246

TABLE 214            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING,

BY COUNTRY, 2022–2030 (USD MILLION)               247

TABLE 215            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING,

BY COUNTRY, 2022–2030 (USD MILLION)               247

TABLE 216            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING,

BY COUNTRY, 2022–2030 (USD MILLION)               248

TABLE 217            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR GLUCOSE MONITORING,

BY COUNTRY, 2022–2030 (USD MILLION)               248

TABLE 218            IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY REGION,

2022–2030 (USD MILLION)            249

TABLE 219            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY,

BY COUNTRY, 2022–2030 (USD MILLION)               249

TABLE 220            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)                 250

TABLE 221            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)                 250

TABLE 222            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)            251

TABLE 223            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY,

BY COUNTRY, 2022–2030 (USD MILLION)               251

TABLE 224            IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY REGION,

2022–2030 (USD MILLION)            252

TABLE 225            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY,

BY COUNTRY, 2022–2030 (USD MILLION)               252

TABLE 226            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)                 253

TABLE 227            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)                 253

TABLE 228            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY,

BY COUNTRY, 2022–2030 (USD MILLION)               254

TABLE 229            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY,

BY COUNTRY, 2022–2030 (USD MILLION)               254

TABLE 230            IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY REGION, 2022–2030 (USD MILLION)            255

TABLE 231            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION)            256

TABLE 232            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS,

BY COUNTRY, 2022–2030 (USD MILLION)               256

TABLE 233            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION) 257

TABLE 234            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION)            257

TABLE 235            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2030 (USD MILLION)            258

TABLE 236            KEY BLOOD GAS ANALYZERS AVAILABLE WORLDWIDE     259

TABLE 237            IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY REGION,

2022–2030 (USD MILLION)          259

TABLE 238            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS, BY COUNTRY, 2022–2030 (USD MILLION) 260

TABLE 239            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS,

BY COUNTRY, 2022–2030 (USD MILLION)               260

TABLE 240            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS,

BY COUNTRY, 2022–2030 (USD MILLION)               261

TABLE 241            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZERS,

BY COUNTRY, 2022–2030 (USD MILLION)             261

TABLE 242            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GAS ANALYZER,

BY COUNTRY, 2022–2030 (USD MILLION)               262

TABLE 243            IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY REGION,

2022–2030 (USD MILLION)            263

TABLE 244            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS,

BY COUNTRY, 2022–2030 (USD MILLION)             263

TABLE 245            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY,

2022–2030 (USD MILLION)            264

TABLE 246            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION)                 264

TABLE 247            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION)            265

TABLE 248            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2030 (USD MILLION)            265

TABLE 249            IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY REGION, 2022–2030 (USD MILLION)            266

TABLE 250            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION)     267

TABLE 251            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION)            267

TABLE 252            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION)     268

TABLE 253            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION)     268

TABLE 254            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2030 (USD MILLION)     269

TABLE 255          IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)            271

TABLE 256            KEY BLOOD, SERUM, AND PLASMA SAMPLE TYPE-BASED

PRODUCTS AVAILABLE WORLDWIDE    272

TABLE 257            IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND

PLASMA SPECIMENS, BY REGION, 2022–2030 (USD MILLION)                 273

TABLE 258            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)     273

TABLE 259            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)       274

TABLE 260            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)            274

TABLE 261            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM,

AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)            275

TABLE 262            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM,

AND PLASMA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)            275

TABLE 263            IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY REGION,

2022–2030 (USD MILLION)            276

TABLE 264            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS,

BY COUNTRY, 2022–2030 (USD MILLION)               276

TABLE 265            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)                 277

TABLE 266            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS,

BY COUNTRY, 2022–2030 (USD MILLION)               277

TABLE 267            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS,

BY COUNTRY, 2022–2030 (USD MILLION)               278

TABLE 268            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SALIVA SPECIMENS,

BY COUNTRY, 2022–2030 (USD MILLION)               278

TABLE 269            KEY URINE SAMPLE TYPE-BASED PRODUCTS AVAILABLE WORLDWIDE             279

TABLE 270            IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY REGION,

2022–2030 (USD MILLION)            280

TABLE 271            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS,

BY COUNTRY, 2022–2030 (USD MILLION)               280

TABLE 272            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)                 281

TABLE 273            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS,

BY COUNTRY, 2022–2030 (USD MILLION)               281

TABLE 274            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS,

BY COUNTRY, 2022–2030 (USD MILLION)               282

TABLE 275            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINE SPECIMENS,

BY COUNTRY, 2022–2030 (USD MILLION)               282

TABLE 276            IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY REGION,

2022–2030 (USD MILLION)            283

TABLE 277            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS,

BY COUNTRY, 2022–2030 (USD MILLION)               283

TABLE 278            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2030 (USD MILLION)                 284

TABLE 279            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS,

BY COUNTRY, 2022–2030 (USD MILLION)               284

TABLE 280            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS,

BY COUNTRY, 2022–2030 (USD MILLION)             285

TABLE 281            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS,

BY COUNTRY, 2022–2030 (USD MILLION)               285

TABLE 282            IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING, 2022–2030 (USD MILLION)        287

TABLE 283            IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)            290

TABLE 284            IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY REGION,

2022–2030 (USD MILLION)            290

TABLE 285            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS,

BY COUNTRY, 2022–2030 (USD MILLION)               291

TABLE 286            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2030 (USD MILLION)                 291

TABLE 287            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS,

BY COUNTRY, 2022–2030 (USD MILLION)               292

TABLE 288            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS,

BY COUNTRY, 2022–2030 (USD MILLION)               292

TABLE 289            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS,

BY COUNTRY, 2022–2030 (USD MILLION)             293

TABLE 290            IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)                 295

TABLE 291            IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS, BY REGION,

2022–2030 (USD MILLION)            296

TABLE 292            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS,

BY COUNTRY, 2022–2030 (USD MILLION)               296

TABLE 293            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS,

BY COUNTRY, 2022–2030 (USD MILLION)             297

TABLE 294            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS,

BY COUNTRY, 2022–2030 (USD MILLION)               297

TABLE 295            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS,

BY COUNTRY, 2022–2030 (USD MILLION)             298

TABLE 296            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTS,

BY COUNTRY, 2022–2030 (USD MILLION)               298

TABLE 297            IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              300

TABLE 298            IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION,

2022–2030 (USD MILLION)            302

TABLE 299            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2022–2030 (USD MILLION)               302

TABLE 300            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2022–2030 (USD MILLION)               303

TABLE 301            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2022–2030 (USD MILLION)               303

TABLE 302            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2022–2030 (USD MILLION)               304

TABLE 303            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2022–2030 (USD MILLION)               304

TABLE 304            INCREASING INCIDENCE OF CANCER, BY REGION, 2022 VS. 2040    305

TABLE 305            LIST OF APPROVED COMPANION DIAGNOSTIC DEVICES, 2022–2024          306

TABLE 306            IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION,

2022–2030 (USD MILLION)            306

TABLE 307            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY,

BY COUNTRY, 2022–2030 (USD MILLION)               306

TABLE 308            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY,

2022–2030 (USD MILLION)            307

TABLE 309            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)                 307

TABLE 310            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)            308

TABLE 311            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)            308

TABLE 312            IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY REGION,

2022–2030 (USD MILLION)            309

TABLE 313            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY,

BY COUNTRY, 2022–2030 (USD MILLION)               310

TABLE 314            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)                 310

TABLE 315            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY,

BY COUNTRY, 2022–2030 (USD MILLION)               311

TABLE 316            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY,

BY COUNTRY, 2022–2030 (USD MILLION)               311

TABLE 317            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY,

BY COUNTRY, 2022–2030 (USD MILLION)               312

TABLE 318            IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY REGION,

2022–2030 (USD MILLION)            313

TABLE 319            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY,

BY COUNTRY, 2022–2030 (USD MILLION)               313

TABLE 320            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY,

2022–2030 (USD MILLION)            314

TABLE 321            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)                 314

TABLE 322            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2030 (USD MILLION)            315

TABLE 323            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY,

BY COUNTRY, 2022–2030 (USD MILLION)               315

TABLE 324            IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY REGION,

2022–2030 (USD MILLION)            316

TABLE 325            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING,

BY COUNTRY, 2022–2030 (USD MILLION)               317

TABLE 326            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2030 (USD MILLION)                 317

TABLE 327            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING,

BY COUNTRY, 2022–2030 (USD MILLION)             318

TABLE 328            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING,

BY COUNTRY, 2022–2030 (USD MILLION)               318

TABLE 329            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING,

BY COUNTRY, 2022–2030 (USD MILLION)               319

TABLE 330            IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION,

2022–2030 (USD MILLION)            320

TABLE 331            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING,

BY COUNTRY, 2022–2030 (USD MILLION)               320

TABLE 332            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2030 (USD MILLION)                 321

TABLE 333            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING,

BY COUNTRY, 2022–2030 (USD MILLION)               321

TABLE 334            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING,

BY COUNTRY, 2022–2030 (USD MILLION)               322

TABLE 335            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING,

BY COUNTRY, 2022–2030 (USD MILLION)             322

TABLE 336            IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY REGION,

2022–2030 (USD MILLION)            324

TABLE 337            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 324

TABLE 338            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES,

BY COUNTRY, 2022–2030 (USD MILLION)               325

TABLE 339            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES,

BY COUNTRY, 2022–2030 (USD MILLION)               325

TABLE 340            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES,

BY COUNTRY, 2022–2030 (USD MILLION)               326

TABLE 341            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2030 (USD MILLION) 326

TABLE 342            IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION,

2022–2030 (USD MILLION)            327

TABLE 343            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS,

BY COUNTRY, 2022–2030 (USD MILLION)               328

TABLE 344            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS,

BY COUNTRY, 2022–2030 (USD MILLION)               328

TABLE 345            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS,

BY COUNTRY, 2022–2030 (USD MILLION)               329

TABLE 346            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS,

BY COUNTRY, 2022–2030 (USD MILLION)             329

TABLE 347            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS,

BY COUNTRY, 2022–2030 (USD MILLION)               330

TABLE 348            KEY PRODUCTS FOR DRUG MONITORING WORLDWIDE     331

TABLE 349            KEY IVD PRODUCTS FOR DRUG TESTING WORLDWIDE     331

TABLE 350            IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2022–2030 (USD MILLION)            332

TABLE 351            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION)            332

TABLE 352            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING,

BY COUNTRY, 2022–2030 (USD MILLION)               333

TABLE 353            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION) 333

TABLE 354            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION)            334

TABLE 355            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2030 (USD MILLION)            334

TABLE 356            KEY PRODUCTS FOR BONE & MINERAL DISORDERS WORLDWIDE            336

TABLE 357            IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2022–2030 (USD MILLION)                 336

TABLE 358            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION)            336

TABLE 359            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS,

BY COUNTRY, 2022–2030 (USD MILLION)               337

TABLE 360            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION) 337

TABLE 361            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION)            338

TABLE 362            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2022–2030 (USD MILLION)            338

TABLE 363            IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY REGION,

2022–2030 (USD MILLION)            339

TABLE 364            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2022–2030 (USD MILLION)       339

TABLE 365            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING,

BY COUNTRY, 2022–2030 (USD MILLION)               340

TABLE 366            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING,

BY COUNTRY, 2022–2030 (USD MILLION)               340

TABLE 367            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING,

BY COUNTRY, 2022–2030 (USD MILLION)               341

TABLE 368            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING,

BY COUNTRY, 2022–2030 (USD MILLION)               341

TABLE 369            IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY REGION,

2022–2030 (USD MILLION)            342

TABLE 370            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING,

BY COUNTRY, 2022–2030 (USD MILLION)               343

TABLE 371            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING,

BY COUNTRY, 2022–2030 (USD MILLION)               343

TABLE 372            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING,

BY COUNTRY, 2022–2030 (USD MILLION)               344

TABLE 373            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING,

BY COUNTRY, 2022–2030 (USD MILLION)               344

TABLE 374            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING,

BY COUNTRY, 2022–2030 (USD MILLION)               345

TABLE 375            IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION,

2022–2030 (USD MILLION)            346

TABLE 376            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2022–2030 (USD MILLION)               346

TABLE 377            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2022–2030 (USD MILLION)               347

TABLE 378            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2022–2030 (USD MILLION)               347

TABLE 379            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2022–2030 (USD MILLION)               348

TABLE 380            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2022–2030 (USD MILLION)               348

TABLE 381            IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)            350

TABLE 382            IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION,

2022–2030 (USD MILLION)          352

TABLE 383            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2022–2030 (USD MILLION)               352

TABLE 384            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2022–2030 (USD MILLION)               353

TABLE 385            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2022–2030 (USD MILLION)             353

TABLE 386            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2022–2030 (USD MILLION)               354

TABLE 387            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2022–2030 (USD MILLION)               354

TABLE 388            IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE,

2022–2030 (USD MILLION)            355

TABLE 389            IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022–2030 (USD MILLION)            355

TABLE 390            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)       356

TABLE 391            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,

BY COUNTRY, 2022–2030 (USD MILLION)             356

TABLE 392            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,

BY COUNTRY, 2022–2030 (USD MILLION)               357

TABLE 393            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)       357

TABLE 394            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)       358

TABLE 395            IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY REGION, 2022–2030 (USD MILLION)            359

TABLE 396            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)            359

TABLE 397            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION) 360

TABLE 398            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)       360

TABLE 399            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)            361

TABLE 400            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)            361

TABLE 401            IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY REGION, 2022–2030 (USD MILLION) 362

TABLE 402            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)     362

TABLE 403            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)            363

TABLE 404            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)            363

TABLE 405            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)     364

TABLE 406            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)     364

TABLE 407            IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY REGION,

2022–2030 (USD MILLION)            365

TABLE 408            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS,

BY COUNTRY, 2022–2030 (USD MILLION)               366

TABLE 409            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2030 (USD MILLION)                 366

TABLE 410            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2030 (USD MILLION)                 367

TABLE 411            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS,

BY COUNTRY, 2022–2030 (USD MILLION)               367

TABLE 412            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS,

BY COUNTRY, 2022–2030 (USD MILLION)               368

TABLE 413            IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION,

2022–2030 (USD MILLION)            369

TABLE 414            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,

BY COUNTRY, 2022–2030 (USD MILLION)               370

TABLE 415            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,

BY COUNTRY, 2022–2030 (USD MILLION)               370

TABLE 416            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,

BY COUNTRY, 2022–2030 (USD MILLION)               371

TABLE 417            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,

BY COUNTRY, 2022–2030 (USD MILLION)               371

TABLE 418            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,

BY COUNTRY, 2022–2030 (USD MILLION)               372

TABLE 419            IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2030 (USD MILLION)          373

TABLE 420            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)   373

TABLE 421            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)     374

TABLE 422            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)     374

TABLE 423            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)   375

TABLE 424            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2030 (USD MILLION)   375

TABLE 425            IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY REGION,

2022–2030 (USD MILLION)            376

TABLE 426            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES,

BY COUNTRY, 2022–2030 (USD MILLION)               376

TABLE 427            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES,

BY COUNTRY, 2022–2030 (USD MILLION)               377

TABLE 428            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES,

BY COUNTRY, 2022–2030 (USD MILLION)               377

TABLE 429            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES,

BY COUNTRY, 2022–2030 (USD MILLION)               378

TABLE 430            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES,

BY COUNTRY, 2022–2030 (USD MILLION)               378

TABLE 431            IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION,

2022–2030 (USD MILLION)            379

TABLE 432            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2030 (USD MILLION)               379

TABLE 433            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION)                 380

TABLE 434            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2030 (USD MILLION)             380

TABLE 435            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2030 (USD MILLION)               381

TABLE 436            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2030 (USD MILLION)               381

TABLE 437            IN VITRO DIAGNOSTICS MARKET, BY REGION, 2022–2030 (USD MILLION)            383

TABLE 438            NORTH AMERICA: KEY MACROECONOMIC INDICATORS      384

TABLE 439            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            386

TABLE 440            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)                 386

TABLE 441            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            387

TABLE 442            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)            388

TABLE 443            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,

BY TYPE, 2022–2030 (USD MILLION)         388

TABLE 444            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 389

TABLE 445            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            389

TABLE 446            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            390

TABLE 447            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            390

TABLE 448            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            391

TABLE 449            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 391

TABLE 450            US: KEY MACROECONOMIC INDICATORS                 393

TABLE 451            US: NUMBER OF IN VITRO DIAGNOSTICS TESTS CONDUCTED,

2022–2030 (BILLION)       393

TABLE 452            US: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            393

TABLE 453            US: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            394

TABLE 454            US: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,

2022–2030 (USD MILLION)            394

TABLE 455            US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE,

2022–2030 (USD MILLION)            395

TABLE 456            US: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)                 395

TABLE 457            US: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)     396

TABLE 458            US: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)                396

TABLE 459            US: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              397

TABLE 460            US: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)                398

TABLE 461            US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)                 398

TABLE 462            CANADA: ESTIMATED PREVALENCE OF DIABETES, 2024 VS. 2034                 399

TABLE 463            CANADA: KEY MACROECONOMIC INDICATORS                 400

TABLE 464            CANADA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            400

TABLE 465            CANADA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            401

TABLE 466            CANADA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,

2022–2030 (USD MILLION)            401

TABLE 467            CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)                 402

TABLE 468            CANADA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,

BY TYPE, 2022–2030 (USD MILLION)         402

TABLE 469            CANADA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            403

TABLE 470            CANADA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            403

TABLE 471            CANADA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)          404

TABLE 472            CANADA: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            404

TABLE 473            CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,

BY TYPE, 2022–2030 (USD MILLION)         405

TABLE 474            EUROPE: KEY MACROECONOMIC INDICATORS                 406

TABLE 475            EUROPE: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            407

TABLE 476            EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            407

TABLE 477            EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            408

TABLE 478            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,

2022–2030 (USD MILLION)            408

TABLE 479            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)                 409

TABLE 480            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,

BY TYPE, 2022–2030 (USD MILLION)         409

TABLE 481            EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)          410

TABLE 482            EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            410

TABLE 483            EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            411

TABLE 484            EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            412

TABLE 485            EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)                 412

TABLE 486            GERMANY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            414

TABLE 487            GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            414

TABLE 488            GERMANY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)                 415

TABLE 489            GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,

BY TYPE, 2022–2030 (USD MILLION)         415

TABLE 490            GERMANY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,

BY TYPE, 2022–2030 (USD MILLION)         416

TABLE 491            GERMANY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            416

TABLE 492            GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            417

TABLE 493            GERMANY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            417

TABLE 494            GERMANY: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            418

TABLE 495            GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,

BY TYPE, 2022–2030 (USD MILLION)         418

TABLE 496            FRANCE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            419

TABLE 497            FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            420

TABLE 498            FRANCE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS,

BY TYPE, 2022–2030 (USD MILLION)         420

TABLE 499            FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,

BY TYPE, 2022–2030 (USD MILLION)         421

TABLE 500            FRANCE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,

BY TYPE, 2022–2030 (USD MILLION)         421

TABLE 501            FRANCE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            422

TABLE 502            FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            422

TABLE 503            FRANCE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            423

TABLE 504            FRANCE: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            423

TABLE 505            FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,

BY TYPE, 2022–2030 (USD MILLION)         424

TABLE 506            UK: KEY MACROECONOMIC INDICATORS                 425

TABLE 507            UK: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            426

TABLE 508            UK: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            426

TABLE 509            UK: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,

2022–2030 (USD MILLION)            427

TABLE 510            UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE,

2022–2030 (USD MILLION)            427

TABLE 511            UK: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)                 428

TABLE 512            UK: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)     428

TABLE 513            UK: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)                429

TABLE 514            UK: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              429

TABLE 515            UK: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)                430

TABLE 516            UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)                 430

TABLE 517            ITALY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            431

TABLE 518            ITALY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            432

TABLE 519            ITALY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,

2022–2030 (USD MILLION)          432

TABLE 520            ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)                 433

TABLE 521            ITALY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)                 433

TABLE 522            ITALY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)     434

TABLE 523            ITALY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)   434

TABLE 524            ITALY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            435

TABLE 525            ITALY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)     435

TABLE 526            ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)                 436

TABLE 527            SPAIN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            437

TABLE 528            SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            437

TABLE 529            SPAIN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,

2022–2030 (USD MILLION)            438

TABLE 530            SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)                 438

TABLE 531            SPAIN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)                 439

TABLE 532            SPAIN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)          439

TABLE 533            SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            440

TABLE 534            SPAIN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            440

TABLE 535            SPAIN: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            441

TABLE 536            SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)                 441

TABLE 537            RUSSIA: KEY MACROECONOMIC INDICATORS                 442

TABLE 538            RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            442

TABLE 539            RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            443

TABLE 540            RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,

2022–2030 (USD MILLION)            443

TABLE 541            RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)                 444

TABLE 542            RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,

BY TYPE, 2022–2030 (USD MILLION)       444

TABLE 543            RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            445

TABLE 544            RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            445

TABLE 545            RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            446

TABLE 546            RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)          446

TABLE 547            RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,

BY TYPE, 2022–2030 (USD MILLION)         447

TABLE 548            SWITZERLAND: KEY MACROECONOMIC INDICATORS      448

TABLE 549            SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            448

TABLE 550            SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)          449

TABLE 551            SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)            449

TABLE 552            SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,

BY TYPE, 2022–2030 (USD MILLION)         450

TABLE 553            SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 450

TABLE 554            SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            451

TABLE 555            SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)          451

TABLE 556            SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            452

TABLE 557            SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            453

TABLE 558            SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,

BY TYPE, 2022–2030 (USD MILLION)         453

TABLE 559            REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)                 454

TABLE 560            REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            455

TABLE 561            REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS,

BY TYPE, 2022–2030 (USD MILLION)         455

TABLE 562            REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,

BY TYPE, 2022–2030 (USD MILLION)         456

TABLE 563            REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 456

TABLE 564            REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            457

TABLE 565            REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            457

TABLE 566            REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            458

TABLE 567            REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            458

TABLE 568            REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 459

TABLE 569            ASIA PACIFIC: KEY MACROECONOMIC INDICATORS      460

TABLE 570            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            462

TABLE 571            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            462

TABLE 572            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            463

TABLE 573            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS,

BY TYPE, 2022–2030 (USD MILLION)         464

TABLE 574            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,

BY TYPE, 2022–2030 (USD MILLION)         464

TABLE 575            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,

BY TYPE, 2022–2030 (USD MILLION)       465

TABLE 576            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            465

TABLE 577            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            466

TABLE 578            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            466

TABLE 579            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            467

TABLE 580            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,

BY TYPE, 2022–2030 (USD MILLION)         467

TABLE 581            JAPAN: KEY MACROECONOMIC INDICATORS                 468

TABLE 582            JAPAN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            469

TABLE 583            JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            469

TABLE 584            JAPAN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,

2022–2030 (USD MILLION)            470

TABLE 585            JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)                 470

TABLE 586            JAPAN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)                 471

TABLE 587            JAPAN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            471

TABLE 588            JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            472

TABLE 589            JAPAN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            472

TABLE 590            JAPAN: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            473

TABLE 591            JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,

BY TYPE, 2022–2030 (USD MILLION)         473

TABLE 592            CHINA: KEY MACROECONOMIC INDICATORS                 474

TABLE 593            CHINA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            474

TABLE 594            CHINA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            475

TABLE 595            CHINA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,

2022–2030 (USD MILLION)            475

TABLE 596            CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)                 476

TABLE 597            CHINA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,

BY TYPE, 2022–2030 (USD MILLION)         476

TABLE 598            CHINA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            477

TABLE 599            CHINA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            477

TABLE 600            CHINA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            478

TABLE 601            CHINA: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            478

TABLE 602            CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)                 479

TABLE 603            INDIA: KEY MACROECONOMIC INDICATORS                 480

TABLE 604            INDIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            480

TABLE 605            INDIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            481

TABLE 606            INDIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,

2022–2030 (USD MILLION)            481

TABLE 607            INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)                 482

TABLE 608            INDIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)                 482

TABLE 609            INDIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)          483

TABLE 610            INDIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)   483

TABLE 611            INDIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)          484

TABLE 612            INDIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)     484

TABLE 613            INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)                 485

TABLE 614            SOUTH KOREA: KEY MACROECONOMIC INDICATORS      486

TABLE 615            SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            486

TABLE 616            SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            487

TABLE 617            SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)            487

TABLE 618            SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,

BY TYPE, 2022–2030 (USD MILLION)         488

TABLE 619            SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 488

TABLE 620            SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            489

TABLE 621            SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            489

TABLE 622            SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            490

TABLE 623            SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            491

TABLE 624            SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,

BY TYPE, 2022–2030 (USD MILLION)         491

TABLE 625            AUSTRALIA: KEY MACROECONOMIC INDICATORS      492

TABLE 626            AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            492

TABLE 627            AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            493

TABLE 628            AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)                 493

TABLE 629            AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,

BY TYPE, 2022–2030 (USD MILLION)       494

TABLE 630            AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,

BY TYPE, 2022–2030 (USD MILLION)         494

TABLE 631            AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            495

TABLE 632            AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)          495

TABLE 633            AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)          496

TABLE 634            AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            496

TABLE 635            AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,

BY TYPE, 2022–2030 (USD MILLION)         497

TABLE 636            SINGAPORE: KEY MACROECONOMIC INDICATORS      497

TABLE 637            SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            498

TABLE 638            SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)          498

TABLE 639            SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)                 499

TABLE 640            SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,

BY TYPE, 2022–2030 (USD MILLION)         499

TABLE 641            SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,

BY TYPE, 2022–2030 (USD MILLION)         500

TABLE 642            SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            500

TABLE 643            SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)          501

TABLE 644            SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            501

TABLE 645            SINGAPORE: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)          502

TABLE 646            SINGAPORE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,

BY TYPE, 2022–2030 (USD MILLION)       502

TABLE 647            REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)                 503

TABLE 648            REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            503

TABLE 649            REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS,

BY TYPE, 2022–2030 (USD MILLION)         504

TABLE 650            REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)            504

TABLE 651            REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 505

TABLE 652            REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            505

TABLE 653            REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            506

TABLE 654            REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            506

TABLE 655            REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            507

TABLE 656            REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 507

TABLE 657            LATIN AMERICA: KEY MACROECONOMIC INDICATORS      508

TABLE 658            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            509

TABLE 659            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            509

TABLE 660            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            510

TABLE 661            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)            510

TABLE 662            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,

BY TYPE, 2022–2030 (USD MILLION)         511

TABLE 663            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 511

TABLE 664            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            512

TABLE 665            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            512

TABLE 666            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            513

TABLE 667            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            514

TABLE 668            LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 514

TABLE 669            BRAZIL: KEY MACROECONOMIC INDICATORS                 515

TABLE 670            BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            516

TABLE 671            BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            516

TABLE 672            BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,

2022–2030 (USD MILLION)            517

TABLE 673            BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)                 517

TABLE 674            BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)                 518

TABLE 675            BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            518

TABLE 676            BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            519

TABLE 677            BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            519

TABLE 678            BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            520

TABLE 679            BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,

BY TYPE, 2022–2030 (USD MILLION)         520

TABLE 680            MEXICO: KEY MACROECONOMIC INDICATORS                 521

TABLE 681            MEXICO: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            522

TABLE 682            MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            522

TABLE 683            MEXICO: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,

2022–2030 (USD MILLION)            523

TABLE 684            MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)                 523

TABLE 685            MEXICO: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,

BY TYPE, 2022–2030 (USD MILLION)         524

TABLE 686            MEXICO: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            524

TABLE 687            MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            525

TABLE 688            MEXICO: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            525

TABLE 689            MEXICO: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            526

TABLE 690            MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)                 526

TABLE 691            REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 527

TABLE 692            REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            528

TABLE 693            REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)       528

TABLE 694            REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)            529

TABLE 695            REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)                529

TABLE 696            REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            530

TABLE 697            REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            530

TABLE 698            REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)            531

TABLE 699            REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            532

TABLE 700            REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)                532

TABLE 701            MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS              533

TABLE 702            MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 534

TABLE 703            MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            534

TABLE 704            MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS,

BY TYPE, 2022–2030 (USD MILLION)         535

TABLE 705            MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)            535

TABLE 706            MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)                536

TABLE 707            MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            536

TABLE 708            MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            537

TABLE 709            MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            537

TABLE 710            MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            538

TABLE 711            MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)                538

TABLE 712            GCC COUNTRIES: KEY MACROECONOMIC INDICATORS      539

TABLE 713            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            539

TABLE 714            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)                 540

TABLE 715            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            540

TABLE 716            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)            541

TABLE 717            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,

BY TYPE, 2022–2030 (USD MILLION)         541

TABLE 718            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 542

TABLE 719            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            542

TABLE 720            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            543

TABLE 721            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            543

TABLE 722            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            544

TABLE 723            GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION) 544

TABLE 724            SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            545

TABLE 725            SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            545

TABLE 726            SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS,

BY TYPE, 2022–2030 (USD MILLION)       546

TABLE 727            SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY,

BY TYPE, 2022–2030 (USD MILLION)         546

TABLE 728            SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION) 547

TABLE 729            SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            547

TABLE 730            SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            548

TABLE 731            SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            548

TABLE 732            SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            549

TABLE 733            SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,

BY TYPE, 2022–2030 (USD MILLION)         549

TABLE 734            UAE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2022–2030 (USD MILLION)            550

TABLE 735            UAE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            551

TABLE 736            UAE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE,

2022–2030 (USD MILLION)            552

TABLE 737            UAE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE,

2022–2030 (USD MILLION)            552

TABLE 738            UAE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)                 553

TABLE 739            UAE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2030 (USD MILLION)     553

TABLE 740            UAE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)                554

TABLE 741            UAE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            554

TABLE 742            UAE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)                555

TABLE 743            UAE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)                 555

TABLE 744            OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 556

TABLE 745            OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            556

TABLE 746            OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2030 (USD MILLION)       557

TABLE 747            OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2022–2030 (USD MILLION)            557

TABLE 748            OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022–2030 (USD MILLION)                558

TABLE 749            OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN,

2022–2030 (USD MILLION)            558

TABLE 750            OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE,

2022–2030 (USD MILLION)            559

TABLE 751            OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)            559

TABLE 752            OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            560

TABLE 753            OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2030 (USD MILLION)                560

TABLE 754            OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS,

JANUARY 2022–APRIL 2025            562

TABLE 755            IN VITRO DIAGNOSTICS MARKET: DEGREE OF COMPETITION 564

TABLE 756            IN VITRO DIAGNOSTICS MARKET: REGION FOOTPRINT       571

TABLE 757            IN VITRO DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT     572

TABLE 758            IN VITRO DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT        573

TABLE 759            IN VITRO DIAGNOSTICS MARKET: END-USER FOOTPRINT       574

TABLE 760            IN VITRO DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES   577

TABLE 761            IN VITRO DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES    578

TABLE 762            IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–APRIL 2025            579

TABLE 763            IN VITRO DIAGNOSTICS MARKET: DEALS, JANUARY 2022–APRIL 2025            580

TABLE 764            IN VITRO DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2022–APRIL 2025            581

TABLE 765            IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–MARCH 2025       583

TABLE 766            IN VITRO DIAGNOSTICS MARKET: DEALS, JANUARY 2022–MARCH 2025         583

TABLE 767            AI-DRIVEN PRODUCTS & SERVICES PROVIDED BY KEY PLAYERS               584

TABLE 768            DANAHER: COMPANY OVERVIEW            585

TABLE 769            DANAHER: PRODUCTS/SERVICES OFFERED                 587

TABLE 770            DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025              590

TABLE 771            DANAHER: DEALS, JANUARY 2022–MARCH 2025                 591

TABLE 772            DANAHER: EXPANSIONS, JANUARY 2022–MARCH 2024        592

TABLE 773            F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW          594

TABLE 774            F. HOFFMANN-LA ROCHE LTD: CURRENCY CONVERSION, 2022–2024                595

TABLE 775            F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED               596

TABLE 776            F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–MARCH 2025         599

TABLE 777            F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2022–MARCH 2025         601

TABLE 778            F. HOFFMANN-LA ROCHE LTD: EXPANSIONS, JANUARY 2022–MARCH 2024         602

TABLE 779            ABBOTT: COMPANY OVERVIEW                603

TABLE 780            ABBOTT: PRODUCTS/SERVICES OFFERED                 604

TABLE 781            ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025              607

TABLE 782            ABBOTT: DEALS, JANUARY 2022–MARCH 2025                 608

TABLE 783            ABBOTT: EXPANSIONS, JANUARY 2022–MARCH 2025        609

TABLE 784            SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW          610

TABLE 785            SIEMENS HEALTHINEERS AG: CURRENCY CONVERSION, 2022–2024                611

TABLE 786            SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES OFFERED               612

TABLE 787            SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025                 614

TABLE 788            SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022–MARCH 2025             614

TABLE 789            SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2022–MARCH 2025         616

TABLE 790            THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW          617

TABLE 791            THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED               618

TABLE 792            THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025                 621

TABLE 793            THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–MARCH 2025         622

TABLE 794          THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–MARCH 2025         624

TABLE 795            ILLUMINA, INC.: COMPANY OVERVIEW 626

TABLE 796            ILLUMINA, INC.: PRODUCTS OFFERED  628

TABLE 797            ILLUMINA, INC.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–MARCH 2025         629

TABLE 798            ILLUMINA, INC.: DEALS, JANUARY 2022–MARCH 2025        630

TABLE 799            ILLUMINA, INC.: EXPANSIONS, JANUARY 2022–MARCH 2025       631

TABLE 800            ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025         632

TABLE 801            HOLOGIC, INC.: COMPANY OVERVIEW  633

TABLE 802            HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED             634

TABLE 803            HOLOGIC, INC.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–MARCH 2025         635

TABLE 804            HOLOGIC, INC.: DEALS, JANUARY 2022–MARCH 2025        636

TABLE 805            HOLOGIC, INC.: EXPANSIONS, JANUARY 2022–MARCH 2025       637

TABLE 806            BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW          638

TABLE 807            BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED               640

TABLE 808            BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025                 642

TABLE 809            BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022–MARCH 2025         643

TABLE 810            BIOMÉRIEUX: COMPANY OVERVIEW      644

TABLE 811            BIOMÉRIEUX: CURRENCY CONVERSION, 2022–2024        645

TABLE 812            BIOMÉRIEUX: PRODUCTS/SERVICES OFFERED                 646

TABLE 813            BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–MARCH 2025         648

TABLE 814            BIOMÉRIEUX: DEALS, JANUARY 2022–MARCH 2025        649

TABLE 815            BIOMÉRIEUX: EXPANSIONS, JANUARY 2022–MARCH 2025       650

TABLE 816            SYSMEX CORPORATION: COMPANY OVERVIEW                 651

TABLE 817            SYSMEX CORPORATION: CURRENCY CONVERSION, 2022–2024                652

TABLE 818            SYSMEX CORPORATION: PRODUCTS/SERVICES OFFERED             653

TABLE 819            SYSMEX CORPORATION: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–MARCH 2025         654

TABLE 820            SYSMEX CORPORATION: DEALS, JANUARY 2022–MARCH 2025       655

TABLE 821            SYSMEX CORPORATION: EXPANSIONS, JANUARY 2022–MARCH 2025         656

TABLE 822            REVVITY: COMPANY OVERVIEW               657

TABLE 823            REVVITY: PRODUCTS/SERVICES OFFERED                 659

TABLE 824            REVVITY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025              660

TABLE 825            REVVITY: DEALS, JANUARY 2022–MARCH 2025                 661

TABLE 826            REVVITY: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025             661

TABLE 827            BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW   662

TABLE 828            BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES OFFERED               663

TABLE 829            BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025        666

TABLE 830            BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2022–MARCH 2025         666

TABLE 831            BECTON, DICKINSON AND COMPANY: EXPANSIONS, JANUARY 2022–MARCH 2025            667

TABLE 832            AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW          668

TABLE 833            AGILENT TECHNOLOGIES, INC: PRODUCTS/SERVICES OFFERED               670

TABLE 834            AGILENT TECHNOLOGIES, INC: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–MARCH 2025         672

TABLE 835            AGILENT TECHNOLOGIES, INC: DEALS, JANUARY 2022–MARCH 2025         673

TABLE 836            AGILENT TECHNOLOGIES, INC: OTHER DEVELOPMENTS,

JANUARY 2022–MARCH 2025         674

TABLE 837            QIAGEN: COMPANY OVERVIEW 675

TABLE 838            QIAGEN: PRODUCTS/SERVICES OFFERED                 677

TABLE 839            QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025              680

TABLE 840            QIAGEN: DEALS, JANUARY 2022–MARCH 2025                 682

TABLE 841            DIASORIN S.P.A.: COMPANY OVERVIEW 683

TABLE 842            DIASORIN S.P.A.: CURRENCY CONVERSION, 2021-2023              684

TABLE 843            DIASORIN S.P.A.: PRODUCTS/SERVICES OFFERED             685

TABLE 844            DIASORIN S.P.A.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–MARCH 2025         687

TABLE 845            DIASORIN S.P.A.: DEALS, JANUARY 2022–MARCH 2025        688

TABLE 846            GRIFOLS, S.A.: COMPANY OVERVIEW      689

TABLE 847            GRIFOLS, S.A.: CURRENCY CONVERSION, 2022–2024        690

TABLE 848            GRIFOLS, S.A.: PRODUCTS/SERVICES OFFERED                 691

TABLE 849            GRIFOLS, S.A.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–MARCH 2025         691

TABLE 850            GRIFOLS, S.A.: DEALS, JANUARY 2022–MARCH 2025        692

TABLE 851            WERFEN: COMPANY OVERVIEW                693

TABLE 852            WERFEN: PRODUCTS/SERVICES OFFERED                 695

TABLE 853            WERFEN: DEALS, JANUARY 2022–MARCH 2025                 696

TABLE 854            WERFEN: EXPANSIONS, JANUARY 2022–MARCH 2025        697

TABLE 855            QUIDELORTHO CORPORATION: COMPANY OVERVIEW          698

TABLE 856            QUIDELORTHO CORPORATION: PRODUCTS/SERVICES OFFERED               700

TABLE 857            QUIDELORTHO CORPORATION: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–MARCH 2025         702

TABLE 858            QUIDELORTHO CORPORATION: DEALS, JANUARY 2022–MARCH 2025         703

TABLE 859            QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2022–MARCH 2024         703

TABLE 860            DEVYSER: COMPANY OVERVIEW              704

TABLE 861            BIOSYNEX SA: COMPANY OVERVIEW      705

TABLE 862            SURMODICS, INC.: COMPANY OVERVIEW                 706

TABLE 863            MENARINI SILICON BIOSYSTEMS: COMPANY OVERVIEW          707

TABLE 864            SPEEDX PTY. LTD.: COMPANY OVERVIEW                 708

TABLE 865            GENSPEED BIOTECH GMBH: COMPANY OVERVIEW          709

TABLE 866            MERCK KGAA: COMPANY OVERVIEW     710

TABLE 867            CARIS LIFE SCIENCES: COMPANY OVERVIEW                 712

TABLE 868            ARKRAY, INC.: COMPANY OVERVIEW     713

TABLE 869            ACCELERATE DIAGNOSTICS, INC.: COMPANY OVERVIEW          714

TABLE 870            CELLABS: COMPANY OVERVIEW               715

TABLE 871            J. MITRA & CO. PVT. LTD.: COMPANY OVERVIEW                 716

TABLE 872            EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW          717

TABLE 873            BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW   718

TABLE 874            ENZO BIOCHEM INC.: COMPANY OVERVIEW                 719

TABLE 875            GENETIC SIGNATURES: COMPANY OVERVIEW                 720

TABLE 876            SAVYON DIAGNOSTICS: COMPANY OVERVIEW                 721

TABLE 877            TRIVITRON HEALTHCARE: COMPANY OVERVIEW          722

TABLE 878            MDXHEALTH: COMPANY OVERVIEW      723

TABLE 879            CREATIVE DIAGNOSTICS: COMPANY OVERVIEW          724

TABLE 880            INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW          725

TABLE 881            MACCURA BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW   726

TABLE 882            LUYE LIFE SCIENCES GROUP: COMPANY OVERVIEW          727

LIST OF FIGURES

FIGURE 1              IN VITRO DIAGNOSTICS MARKET SEGMENTATION AND REGIONAL SCOPE              58

FIGURE 2              RESEARCH DESIGN         62

FIGURE 3              BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS            68

FIGURE 4              BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,

DESIGNATION, AND REGION     68

FIGURE 5              GLOBAL IN VITRO DIAGNOSTICS MARKET: REVENUE SHARE ANALYSIS         69

FIGURE 6              CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS                 70

FIGURE 7              TOP-DOWN APPROACH                71

FIGURE 8              DATA TRIANGULATION METHODOLOGY                 72

FIGURE 9              IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,

2025 VS. 2030 (USD MILLION)    75

FIGURE 10            IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)      76

FIGURE 11           IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2025 VS. 2030 (USD MILLION)      77

FIGURE 12            IN VITRO DIAGNOSTICS MARKET, BY SITE OF TESTING,

2025 VS. 2030 (USD MILLION)      77

FIGURE 13            IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)       78

FIGURE 14            IN VITRO DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)      79

FIGURE 15            GEOGRAPHIC SNAPSHOT OF IN VITRO DIAGNOSTICS MARKET 80

FIGURE 16            GROWING PREVALENCE OF INFECTIOUS DISEASES AND RISING EMPHASIS ON NEED FOR EARLY DIAGNOSIS TO DRIVE MARKET 82

FIGURE 17            REAGENTS & KITS SEGMENT AND US LED NORTH AMERICAN IN VITRO DIAGNOSTICS MARKET IN 2024                 83

FIGURE 18            CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD         84

FIGURE 19            ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD       84

FIGURE 20            EMERGING ECONOMIES TO REGISTER HIGHER GROWTH

DURING FORECAST PERIOD       85

FIGURE 21            IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS,

OPPORTUNITIES, AND CHALLENGES     86

FIGURE 22            IN VITRO DIAGNOSTIC REGULATION: CRITICAL AREAS OF IMPACT           91

FIGURE 23            TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS   98

FIGURE 24            IN VITRO DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS              103

FIGURE 25            IN VITRO DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS              104

FIGURE 26            IN VITRO DIAGNOSTICS MARKET: ECOSYSTEM MAPPING             105

FIGURE 27            IN VITRO DIAGNOSTICS MARKET: INVESTMENT AND

FUNDING SCENARIO, 2020−2023               106

FIGURE 28            IN VITRO DIAGNOSTICS MARKET: PATENT ANALYSIS, 2014–2024       109

FIGURE 29            US: REGULATORY PROCESS FOR IVD DEVICES                 119

FIGURE 30            CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA      120

FIGURE 31            EUROPE: IN VITRO DIAGNOSTIC REGULATION (IVDR) TIMELINE             121

FIGURE 32            REGULATORY PROCESS FOR IVD DEVICES IN JAPAN   122

FIGURE 33            INDIA: REGULATORY PROCESS FOR IVD DEVICES              124

FIGURE 34            MEXICO: REGULATORY PROCESS FOR IVD DEVICES              127

FIGURE 35            IN VITRO DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 129

FIGURE 36            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD PRODUCTS,

BY PRODUCT & SERVICE               131

FIGURE 37            KEY BUYING CRITERIA, BY PRODUCT & SERVICE                 132

FIGURE 38            AI USE CASES     139

FIGURE 39            NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET SNAPSHOT       385

FIGURE 40            ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET SNAPSHOT          461

FIGURE 41            IN VITRO DIAGNOSTICS MARKET: REVENUE ANALYSIS OF KEY PLAYERS,

2022–2024 (USD BILLION)             563

FIGURE 42            IN VITRO DIAGNOSTICS MARKET SHARE ANALYSIS, 2024  564

FIGURE 43            RANKING OF KEY PLAYERS, 2024               566

FIGURE 44            EV/EBITDA OF KEY VENDORS, 2025         566

FIGURE 45            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025            567

FIGURE 46            IN VITRO DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON             567

FIGURE 47            IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2024     569

FIGURE 48            IN VITRO DIAGNOSTICS MARKET: COMPANY FOOTPRINT       570

FIGURE 49            IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 576

FIGURE 50            DANAHER: COMPANY SNAPSHOT (2024)                 586

FIGURE 51            F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)             595

FIGURE 52            ABBOTT: COMPANY SNAPSHOT (2024)  604

FIGURE 53            SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)             611

FIGURE 54            THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)             618

FIGURE 55            ILLUMINA, INC.: COMPANY SNAPSHOT (2024)                 627

FIGURE 56            HOLOGIC, INC.: COMPANY SNAPSHOT (2024)                 634

FIGURE 57            BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)             639

FIGURE 58            BIOMÉRIEUX: COMPANY SNAPSHOT (2024)                 645

FIGURE 59            SYSMEX CORPORATION: COMPANY SNAPSHOT (2024)    652

FIGURE 60            REVVITY: COMPANY SNAPSHOT (2024)  658

FIGURE 61            BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2024)      663

FIGURE 62            AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)             669

FIGURE 63            QIAGEN: COMPANY SNAPSHOT (2024)   676

FIGURE 64            DIASORIN S.P.A: COMPANY SNAPSHOT (2023)                 684

FIGURE 65            GRIFOLS, S.A.: COMPANY SNAPSHOT (2024)                 690

FIGURE 66            WERFEN: COMPANY SNAPSHOT (2024)  694

FIGURE 67            QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2024)             699

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧